IP Verse

Factor Ix Polypeptide Mutant, Its Uses And A Method For Its Production - EP2337849

The patent EP2337849 was granted to Simioni on Jun 13, 2018. The application was originally filed on Sep 15, 2009 under application number EP09748260A. The patent is currently recorded with a legal status of "Revoked".

EP2337849

SIMIONI
Application Number
EP09748260A
Filing Date
Sep 15, 2009
Status
Revoked
Jul 2, 2021
Grant Date
Jun 13, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GREAVES BREWSTERMar 13, 2019GREAVES BREWSTERWITHDRAWN
BAXALTAMar 12, 2019HOFFMANN EITLEADMISSIBLE
PFIZERMar 12, 2019PFIZERADMISSIBLE
WEINZIERLMar 12, 2019SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
STRAWMANDec 17, 2018D YOUNGADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2007149406
INTERNATIONAL-SEARCH-REPORTWO2008092643
INTERNATIONAL-SEARCH-REPORTWO9903496
OPPOSITIONEP2337849
OPPOSITIONEP3252157
OPPOSITIONUS2008167219
OPPOSITIONUS7125841
OPPOSITIONWO0240544
OPPOSITIONWO2008118507
OPPOSITIONWO2009140015
OPPOSITIONWO2010029178
OPPOSITIONWO9903496

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- FRANCHINI MASSIMO ET AL, "Treatment of hemophilia B: focus on recombinant factor IX.", BIOLOGICS : TARGETS & THERAPY 2013, (2013), vol. 7, ISSN 1177-5475, pages 33 - 38-
EXAMINATION- SCHAUB R ET AL, "Preclinical studies of recombinant factor IX", SEMINARS IN HEMATOLOGY, (199804), vol. 35, no. 2 SUPPL. 2, ISSN 0037-1963, pages 28 - 32-
INTERNATIONAL-SEARCH-REPORT- ANSON D S ET AL, "THE GENE STRUCTURE OF HUMAN ANTI-HAEMOPHILIC FACTOR IX", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (19840101), vol. 3, no. 5, ISSN 0261-4189, pages 1053 - 1060, XP000872222 [X] 1-3 * page 1054; figure 2 *-
INTERNATIONAL-SEARCH-REPORT- YAN JING-BIN ET AL, "Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.", BIOCHEMICAL GENETICS OCT 2006, (200610), vol. 44, no. 7-8, ISSN 0006-2928, pages 349 - 360, XP019447249 [X] 1-10 * the whole document *
INTERNATIONAL-SEARCH-REPORT- SIMIONI PAOLO ET AL, "X-linked thrombophilia with a mutant factor IX (factor IX Padua).", THE NEW ENGLAND JOURNAL OF MEDICINE 22 OCT 2009, (20091022), vol. 361, no. 17, ISSN 1533-4406, pages 1671 - 1675, XP002555909 [T] 1-10 * page 1674 - page 1675 *
INTERNATIONAL-SEARCH-REPORT- CHANG JINLI ET AL, "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, (19980515), vol. 273, no. 20, ISSN 0021-9258, pages 12089 - 12094, XP002199691 [XD] 1-10 * the whole document *
INTERNATIONAL-SEARCH-REPORT- MATHUR A ET AL, "Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 JUN 1999, (19990625), vol. 274, no. 26, ISSN 0021-9258, pages 18477 - 18486, XP002555906 [X] 1-10 * page 18480, column L; figure 2 * * page 18481; figures 3,4; table i *
INTERNATIONAL-SEARCH-REPORT- SABATINO DENISE E ET AL, "Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene", BLOOD, (20041101), vol. 104, no. 9, ISSN 0006-4971, pages 2767 - 2774, XP002555908 [A] 1-10 * the whole document *
INTERNATIONAL-SEARCH-REPORT- SCHUETTRUMPF JOERG ET AL, "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, (20050315), vol. 105, no. 6, ISSN 0006-4971, pages 2316 - 2323, XP002555907 [X] 1-10 * the whole document *
OPPOSITION- "Abnormal uterine bleeding", Wikipedia, (20181014), pages 1 - 3, URL: https://en.wikipedia.org/wiki/Abnormal_uterine_bleeding, XP055579032-
OPPOSITION- "BeneFIX@ COAGULATION FACTOR IX (RECOMBINANT", Wyeth W10483COO8, pages 1 - 16, URL: http://www.abopharmaceuticals.com/products/plasmas-
OPPOSITION- BOWEN D.J., "Haemophilia A and haemophilia B: molecular insights", J Clin Pathol : Mol Pathol, (20020000), vol. 55, pages 1 - 18, XP055579036-
OPPOSITION- BRINKHOUS KM et al., "Recom binant Human Factor IX: Replacement Therapy, Prophylaxis, and Pharmacokinetics in Canine Hemophilia B", Blood, (19960000), vol. 88, no. 7, pages 2603 - 2610, XP055575911-
OPPOSITION- "Cardiovascular disease", Wikipedia, (20190217), pages 1 - 25, URL: https://en.wikipedia.org/wiki/Cardiovascular_disease, XP055579043-
OPPOSITION- CHAMBERLAIN C.E., "Acute hemorrhagic gastritis", Gastroenterol Clin North Am., (19930000), vol. 22, no. 4, pages 843 - 873-
OPPOSITION- CHANG et al., "Changing reisdues 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", Journal of Biological Chemistry, (19980000), vol. 272, no. 20, pages 12089 - 12094, XP055542074-
OPPOSITION- FURIE et al., "A Practical Guide to the Evaluation and Treatment of Hemophilia", Blood, (19940701), vol. 84, no. 1, pages 3 - 9, XP055575724-
OPPOSITION- "Hematologic disease", Wikipedia, pages 1 - 4, URL: https://en.wikipedia.org/wiki/Hematologic_disease, XP055579041-
OPPOSITION- SCHAUB et al., "Preclinicals studies of recombinant factor IX", Seminars in Hemotology, (19980000), vol. 35, no. 2, pages 28 - 32, XP055542089-
OPPOSITION- SCHAUB et al., "Preclinical Studies of Recombinant Factor IX", Seminars in Hematology, (19980400), vol. 35, no. 2, pages 28 - 32, XP055575719-
OPPOSITION- SIMIONI et al., "Evidence of the first x-linked thrombophilia due to a novel mutation in clotting factor IX gene resulting in hyperfunctional fix: factor IX arginine 338 leucine (factor IX padua)", International Society on Thrombosis and Hemostasis, (20090000), vol. 7, no. 2, page 1, XP055542100-
OPPOSITION- ROBERTS HR et al., "Current management of hemophilia B", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, (19930000), vol. 7, no. 6, pages 1269 - 1280, XP055575730
OPPOSITION- CHANG et al., "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", The Journal of Biological Chemistry, (19980515), vol. 273, no. 20, pages 12089 - 12094, XP002199691
OPPOSITION- NILSSON et al., "Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B", Journal of Internal Medicine, (19920000), vol. 232, pages 25 - 32, XP055542018
OPPOSITION- Nilsson et al., "Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B", Journal of Internal Medicine, vol. 232, pages 25 - 32, XP055542018
OPPOSITION- SCHUETTRUMPF et al., "Factor IX variants improve gene therapy efficacy for hemophilia B", Blood, (20050315), vol. 105, no. 6, pages 2316 - 2323, XP002555907
OPPOSITION- SCHUETTRUMPF et al., "Factor IX variants improve gene therapy efficacy for hemophilia B", Blood, (20050315), vol. 105, no. 6, pages 2316 - 2323, XP055542043
OPPOSITION- FRANCHINI et al., "Treatment of hemophilia B: focus on recombinant factor IX", Biologics: Targets and Therapy, (20130000), vol. 7, pages 33 - 38, XP055173759

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents